表紙
市場調査レポート

世界におけるHIV/AIDS治療向け抗レトロウイルス薬開発の製品・パイプライン分析

A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

発行 Frost & Sullivan 商品コード 307680
出版日 ページ情報 英文 66 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
世界におけるHIV/AIDS治療向け抗レトロウイルス薬開発の製品・パイプライン分析 A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
出版日: 2014年07月03日 ページ情報: 英文 66 Pages
概要

当レポートでは、HIV/AIDS治療向けの抗ウィルス薬/抗レトロウイルス薬に注目し、上市薬・開発中製品の製品・パイプライン評価、HIV感染治療向けの併用レジメン、薬剤クラス別の区分、治験スケジュール・結果、発売スケジュールの実績・予測、世界における地域・国別の有病率などを提供しています。

第1章 エグゼクティブサマリー

第2章 調査手法・範囲

第3章 イントロダクション

  • HIVの概要
  • HIV/AIDSの有病率:世界・地域別
  • 市場区分

第4章 HIV/AIDS抗レトロウイルス薬市場

  • HIV/AIDS抗レトロウイルス薬市場:上市薬の競合情勢
  • HIV/AIDS抗レトロウイルス薬市場:開発中製品の競合情勢
  • HIV/AIDS抗レトロウイルス薬市場:製品発売・特許消滅のスケジュール
  • HIV/AIDS抗レトロウイルス薬市場:主な第3相治験
  • HIV/AIDS抗レトロウイルス薬市場:最新の主試験結果
  • 上市薬の概要:マルチクラスFDC製品
  • 上市薬の概要:シングルクラスのFDC製品
  • 上市薬の概要:シングルエンティティ製品
  • パイプライン薬の概要:後期段階の開発製品
  • パイプライン薬の概要:初期臨床開発製品
  • パイプライン薬の概要:初期開発製品

第5章 結論・提言

  • 結論・提言
  • 免責事項

第6章 付録

第7章 FROST & SULLIVAN について

目次
Product Code: NE48-52

Antiretroviral Combinations Continue to Transform the Treatment Landscape

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Key Market Developments since Q1 2013
  • 2. Key Findings
  • 3. Evolution of Standard of Care for HIV
  • 4. Key Companies to Watch

2. METHODOLOGY AND SCOPE

  • 1. Methodology and Scope

3. INTRODUCTION

  • 1. HIV Overview
  • 2. HIV Overview (continued)
  • 3. Prevalence of HIV/AIDS Globally and by Region
  • 4. Market Segmentation
  • 5. Market Segmentation (continued)

4. HIV/AIDS ANTIRETROVIRAL MARKET

  • 1. HIV/AIDS Antiretroviral Market-Competitive Landscape ofMarketed Products
  • 2. HIV/AIDS Antiretroviral Market-Competitive Landscape ofProducts in Development
  • 3. HIV/AIDS Antiretroviral Market-Product Launch and Patent Expiration Timeline
  • 4. HIV/AIDS Antiretroviral Market-Major Phase 3 Ongoing Trials
  • 5. HIV/AIDS Antiretroviral Market-Major Phase 3 Ongoing Trials (continued)
  • 6. HIV/AIDS Antiretroviral Market-Recent Pivotal Trial Results
  • 7. HIV/AIDS Antiretroviral Market-Recent Pivotal Trial Results (continued)
  • 8. Marketed Product Synopsis-Multi-class FDC Products
  • 9. Marketed Product Synopsis-Single-class FDC Products
  • 10. Marketed Product Synopsis-Single-entity Products
  • 11. Marketed Product Synopsis-Single-entity Products (continued)
  • 12. Marketed Product Synopsis-Single-entity Products (continued)
  • 13. Marketed Product Synopsis-Single-entity Products (continued)
  • 14. Marketed Product Synopsis-Single-entity Products (continued)
  • 15. Marketed Product Synopsis-Single-entity Products (continued)
  • 16. Marketed Product Synopsis-Single-entity Products (continued)
  • 17. Pipeline Synopsis-Late-stage Development Products
  • 18. Pipeline Synopsis-Late-stage Development Products (continued)
  • 19. Pipeline Synopsis-Late-stage Development Products (continued)
  • 20. Pipeline Synopsis-Late-stage Development Products (continued)
  • 21. Pipeline Synopsis-Late-stage Development Products (continued)
  • 22. Pipeline Synopsis-Late-stage Development Products (continued)
  • 23. Pipeline Synopsis-Early Clinical Development Products
  • 24. Pipeline Synopsis-Early Development Products
  • 25. Pipeline Synopsis-Early Development Products (continued)
  • 26. Pipeline Synopsis-Early Development Products (continued)

5. CONCLUSIONS AND RECOMMENDATIONS

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

6. APPENDIX

  • 1. Decision Support Database-Prevalence of HIV Infection
  • 2. Decision Support Database-Prevalence of HIV Infection (continued)
  • 3. Decision Support Database-Prevalence of HIV Infection (continued)
  • 4. Decision Support Database-Prevalence of HIV Infection (continued)
  • 5. Decision Support Database-Prevalence of HIV Infection (continued)
  • 6. Decision Support Database-Prevalence of HIV Infection (continued)
  • 7. Decision Support Database-Prevalence of HIV Infection (continued)
  • 8. Decision Support Database-Prevalence of HIV Infection (continued)
  • 9. Decision Support Database-Prevalence of HIV Infection (continued)
  • 10. Decision Support Database-Prevalence of HIV Infection (continued)

7. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top